(1) Cyclotek QLD – Site validation completed, building certifier approved, QLD Health and TGA approval achieved by May 2016. Commenced commercial supply of FDG on 30 May 2016.
(2) 18F-DCFPyL in-licence agreement finalised with Johns Hopkins University for use of the F18 PSMA tracer for Prostate cancer for Australia and New Zealand.
(3) Cyclotek undertakes a development plan for the GMP manufacture of 18F-DCFPyL (Prostate Specific Radiopharmaceutical)
[contact-form-7 id=”714″ title=”Update Form”]
